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Risk-Treatment Paradox in the Selection of Transradial Access for
Percutaneous Coronary Intervention
Neil J. Wimmer, MD; Frederic S. Resnic, MD, MSc; Laura Mauri, MD, MSc; Michael E. Matheny, MD, MS, MPH; Thomas C. Piemonte, MD;
Eugene Pomerantsev, MD, PhD; Kalon K. L. Ho, MD, MSc; Susan L. Robbins, BS; Howard M. Waldman, MD, PhD; Robert W. Yeh, MD, MSc
Background-—Access site complications contribute to morbidity and mortality during percutaneous coronary intervention (PCI).
Transradial arterial access signiﬁcantly lowers the risk of access site complications compared to transfemoral arteriotomy. We
sought to develop a prediction model for access site complications in patients undergoing PCI with femoral arteriotomy, and
assess whether transradial access was selectively used in patients at high risk for complications.
Methods and Results-—We analyzed 17 509 patients who underwent PCI without circulatory support from 2008 to 2011 at
5 institutions. Transradial arterial access was used in 17.8% of patients. In those who underwent transfemoral access, 177
(1.2%) patients had access site complications. Using preprocedural clinical and demographic data, a prediction model for femoral
arteriotomy complications was generated. The variables retained in the model included: elevated age (P<0.001), female
gender (P<0.001), elevated troponin (P<0.001), decreased renal function or dialysis (P=0.002), emergent PCI (P=0.01),
prior PCI (P=0.005), diabetes (P=0.008), and peripheral artery disease (P=0.003). The model showed moderate discrimination
(optimism-adjusted c-statistic=0.72) and was internally validated via bootstrap resampling. Patients with higher predicted
risk of complications via transfemoral access were less likely to receive transradial access (P<0.001). Similar results were
seen in patients presenting with and without ST-segment myocardial infarction and when adjusting for individual physician
operator.
Conclusions-—We generated and validated a model for transfemoral access site complications during PCI. Paradoxically, patients
most likely to develop access site complications from transfemoral access, and therefore beneﬁt from transradial access, were the
least likely to receive transradial access. ( J Am Heart Assoc. 2013;2:e000174 doi: 10.1161/JAHA.113.000174)
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B leeding and other access site complications aresigniﬁcant contributors to the morbidity and mortality
associated with percutaneous coronary intervention (PCI).1–9
The use of transradial arterial access signiﬁcantly lowers,
but does not eliminate, the risk of bleeding and other vascular
complications compared with the transfemoral approach.10–16
However, across the United States, the rate of transradial
arterial access remains low. In an analysis of more
than 1.7 million hospital admissions for PCI from the National
Cardiovascular Data Registry (NCDR) CathPCI database
from 2005 to 2009, the rate of transradial arterial
access for PCI was <1.5%.17 As operator enthusiasm and
experience with transradial access grow, the utilization of this
approach is likely to increase signiﬁcantly over the next
several years.
As with other interventions and therapies, the magnitude
of beneﬁt associated with transradial access is likely to vary
widely among patients, depending primarily on patient risk of
femoral vascular access complications. As transradial arterial
access for PCI becomes more widely adopted, ensuring that it
is used preferentially in patients at highest risk of vascular
access complications is essential for optimizing patient
outcomes and avoiding the pitfalls of the “risk-treatment
paradox”—the phenomenon that interventions are often least
used in patients expected to beneﬁt the most from them.18
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However, tools to enable clinicians to stratify patients on the
basis of their risk for access-site complications are currently
limited.
The purpose of this analysis was 2-fold. First, we sought to
develop a prediction model for access site complications using
preprocedural clinical and demographic factors in patients
undergoing PCI via transfemoral arterial access in the current
era. Second, we sought to assess whether transradial arterial
access was rationally applied as a complication avoidance
strategy by being performed in patients at the highest risk for
complications via the transfemoral approach.
Methods
Study Population
Data were obtained on consecutive patients who underwent
PCI without intra-aortic balloon pump or other mechanical
circulatory support from January 1, 2008 through December
31, 2011 at 5 institutions in Massachusetts using either
transfemoral or transradial arterial access. The institutions
included Brigham and Women’s Hospital, Massachusetts
General Hospital, Beth Israel Deaconess Medical Center, the
Lahey Clinic, and North Shore Medical Center. Deidentiﬁed,
patient-level data were extracted using the NCDR CathPCI
Registry forms versions 3 or 4 as part of the Data
Extraction and Longitudinal Trend Analysis (DELTA) network
study.19 PCI was performed according to standard clinical
practice.
Deﬁnitions
The dataset is based on the American College of Cardiology—
National Cardiovascular Data Registry deﬁnitions and con-
tains clinical and procedural elements for each patient and
follow-up information for the occurrence of all in-hospital
complications.20,21 A full description of the data element
deﬁnitions for the CathPCI registry is available online at
http://www.ncdr.com/WebNCDR/ELEMENTS.ASPX.
The outcome of interest was vascular access site compli-
cations, which were deﬁned as one of the following occurring
during the index hospitalization: access site bleeding requiring
transfusion, access site bleeding causing hematoma >5 cm,
retroperitoneal bleeding, other vascular complications requir-
ing diagnostic testing or therapy (for instance, pseudoaneu-
rysm), or death from a vascular cause.
We considered a range of candidate predictors for possible
inclusion in the prediction model based on clinical relevance.
These factors included demographic information, factors
related to the general medical history (including body mass
index), factors related to the cardiovascular history, factors
related to the acute presentation (including the presence of
clinical shock, whether the PCI was emergent, the presence of
ST-segment elevation myocardial infarction [STEMI], current
renal function, etc), and factors known to be associated with
PCI-related bleeding or mortality.22,23
Statistical Approach
Continuous variables were described as means (standard
deviation) and were compared using t-tests due to large
sample size. Categorical variables were described as percent-
ages and compared using chi-square or Fisher exact tests. We
modeled in-hospital vascular access site complications among
patients who had transfemoral arterial access using multivar-
iable logistic regression methods. Models were generated
using backward selection with univariate prescreening of
candidate predictors (P<0.2 for entry, P<0.05 for retention).
After univariate screening, 15 variables were considered for
retention in the ﬁnal model. These variables included: age,
female sex, prior congestive heart failure, history of diabetes
mellitus, history of chronic lung disease, history of hyperten-
sion, history of peripheral artery disease, chronic kidney
disease (glomerular ﬁltration rate ≥60 mL min1 1.73 m2,
<60 mL min1 1.73 m2, or on chronic dialysis), history of
prior valvular heart surgery, whether the procedure was
emergent, the presence of an elevated troponin (either
troponin T or troponin I) prior to the procedure, presentation
with STEMI, or presentation with non-ST segment myocardial
infarction.
Model discrimination was assessed with the c-statistic.
Model calibration was assessed by plotting a smoothed line of
observed versus predicted probabilities of vascular complica-
tions within the femoral PCI population, as well as via the
Hosmer–Lemeshow chi-square test.24 We internally validated
the model in 1000 bootstrap samples (resampling with
replacement), as this method has been shown to perform
more reliably than other methods of internal validation.25,26
Final reported estimates of model discrimination and calibra-
tion were reduced to account for optimism based on
previously described methods.25 Model coefﬁcients were
adjusted based on a calculation of the linear calibration slope
in order to adjust for overﬁtting.25,27
The prediction model for femoral access site complications
was then applied to all patients in the study sample, including
those who received PCI via a transradial approach. Patients in
both the transfemoral and transradial groups were stratiﬁed
into risk categories of <1% risk of complications, 1% to 2% risk
of complications, and >2% risk of complications. Comparisons
of the percentage of patients receiving transradial access
compared to transfemoral access were then made across risk
groups. Similar analyses were performed in individuals who
presented with STEMI, those who did not present with STEMI,
as well as in the overall population excluding patients
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receiving dialysis treatment. We additionally quantiﬁed the
relationship between risk of vascular complications with a
transfemoral approach and the actual receipt of transradial
access using logistic regression.
To account for the individual physician operator in the
relationship between the risk of transfemoral vascular access
site complications and the use of transradial access, we
generated a 2-level mixed effects logistic regression model
with a random effect for the physician operator. Patients were
included in this model if the physician performing the PCI had
performed at least 25 procedures in the time under study.
Individual physician operator information was available from 4
of the 5 clinical sites.
Analyses were performed using STATA 11.2 (Statacorp)
and R (version 2.15.0). The study was Institutional Review
Board approved by the Partners Human Research Committee.
Results
A total of 17 509 patients undergoing PCI met the inclusion
criteria for this analysis. Transfemoral arterial access was
used in 14 387 (82.2%) patients and transradial arterial
access was used in 3122 (17.8%) patients. Baseline charac-
teristics overall, and stratiﬁed by arterial access site, are
shown in Table 1.
In the group who received PCI via a transfemoral approach,
177 (1.2%) patients had vascular access site complications.
Access site hematomas occurred in 102 patients, bleeding
requiring treatment with transfusion occurred in 69, and other
vascular complications including retroperitoneal bleeding or
pseudoaneurysm occurred in 50 patients. There were 9
patients with death from a vascular cause.
The ﬁnal model predicting vascular access site complica-
tions in those who had transfemoral arterial access had 8
signiﬁcant predictors including elevated age, female gender,
elevated troponin, chronic kidney disease, emergent proce-
dure, prior PCI, diabetes, and peripheral artery disease
(Table 2). The unadjusted c-statistic of the model was 0.76,
and was 0.72 after adjusting for optimism, demonstrating
moderate discrimination for the model. After bootstrap
resampling, a plot of observed versus predicted rates of
vascular complications suggested good model calibration
(calibration slope=0.92, Hosmer–Lemeshow goodness of
ﬁt=0.42). (Figure 1).
After application of the model predicting femoral vascular
complications to all patients, including those who received
transradial arterial access, patients with the highest predicted
risk of complications via transfemoral arterial access were
less likely to receive transradial access (P<0.001) (Figure 2).
Similar results were seen in patients presenting for PCI with
STEMI (P<0.001) and in those presenting without STEMI
(P<0.001) (Figure 3). Similar results were also seen when the
model was applied to the full study population excluding
patients receiving dialysis treatment, for whom transradial
Table 1. Baseline Characteristics of Patients Undergoing PCI Via the Transfemoral or Transradial Approach
Variable Total (n=17 509) Femoral (n=14 387) Radial (n=3122) P Value
Age (standard deviation), y 65.9 (12.2) 66.3 (12.2) 64.2 (11.8) <0.001
Male, % 71.5 70.7 75.3 <0.001
Black, % 3.6 3.5 4.3 0.038
Prior myocardial infarction, % 32.9 33.5 30.2 <0.001
Prior heart failure, % 12.0 13.2 8.2 <0.001
Diabetes, % 32.7 33.9 32.1 0.057
Chronic lung disease, % 13.6 13.7 13.4 0.62
Prior PCI, % 35.8 37.5 32.9 <0.001
Prior CABG, % 17.4 19.7 9.5 <0.001
Hypertension, % 82.0 82.2 81.3 0.212
Peripheral artery disease, % 13.7 14.2 11.8 0.001
Dialysis, % 1.8 2.1 0.7 <0.001
Cardiogenic shock, % 0.6 0.7 0.3 0.009
Emergent procedure, % 15.1 15.4 13.9 0.042
Troponin positive, % 32.8 31.9 36.9 <0.001
STEMI, % 12.4 12.4 12.5 0.922
PCI indicates percutaneous coronary intervention; CABG, coronary artery bypass grafting surgery; STEMI, ST-segment myocardial infarction.
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access might have been limited due to the presence of
arteriovenous ﬁstulas or the desire to preserve future
hemodialysis access sites (P<0.001) (Figure 3).
To quantify the relationship between the risk of transfe-
moral access site complications and the receipt of transradial
arterial access, we generated logistic regression models. The
odds ratio associated with the receipt of transradial access
was 0.86 (95% CI, 0.82 to 0.90, P<0.0001) for each 1%
increase in risk of transfemoral access site complications.
Similarly, after adjusting for individual physician operators,
the odds ratio associated with the receipt of transradial
access was 0.83 (95% CI, 0.77 to 0.87, P<0.0001) for each
1% increase in risk of transfemoral access site complications.
Discussion
We developed a model for vascular access site complications
in patients undergoing PCI via a transfemoral arterial
approach in a contemporary registry from 5 hospitals in
Figure 1. Observed vs predicted rates of vascular complications.
This ﬁgure depicts observed (y-axis) vs predicted (x-axis) vascular
access site complications in patients undergoing percutaneous
coronary intervention (PCI) via transfemoral access. The bias-
corrected line represents the adjusted calibration curve accounting
for optimism, as assessed by bootstrap validation. Differences in
observed and predicted rates of events were small across all levels of
risk (Hosmer–Lemeshow P=0.42).
Figure 2. Rate of femoral or radial access according to predicted
risk of transfemoral vascular access complications. Patients with
higher predicted risk of complications via the transfemoral approach
were less likely to receive a transradial approach (P<0.001).
Table 2. Final Model for Vascular Complications in Patients Who Had Transfemoral Arterial Access
Variable b OR Calibrated b Calibrated OR 95% CI for Calibrated OR
Age (per 10 years) 0.262 1.300 0.241 1.272 1.119 to 1.449
Female (y/n) 0.980 2.664 0.902 2.464 1.845 to 3.289
Troponin elevated (y/n) 0.713 2.041 0.656 1.927 2.509 to 2.584
Chronic kidney disease
GFR ≥60 mL min1 1.73 m2 Ref Ref Ref Ref Ref
GFR <60 mL min1 1.73 m2 0.245 1.278 0.225 1.252 0.914 to 1.718
Dialysis (y/n) 1.137 3.120 1.046 2.846 1.537 to 4.985
Emergent case (y/n) 0.478 1.612 0.439 1.551 1.100 to 2.188
Prior PCI (y/n) 0.495 0.610 0.455 0.634 0.460 to 0.874
PAD (y/n) 0.549 1.732 0.505 1.657 1.187 to 2.316
Diabetes (y/n) 0.430 1.537 0.396 1.486 1.110 to 1.985
Constant 7.26 6.679
OR indicates odds ratio; CI, conﬁdence interval; GFR, glomerular ﬁltration rate; Ref, reference; PCI, percutaneous coronary intervention; PAD, peripheral artery disease.
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Massachusetts. This model accounts for access site compli-
cations beyond bleeding alone, and therefore better reﬂects
the true range of possible complications associated with PCI-
related arterial access. The model also ignores bleeding
complications physically isolated from the arterial access site,
such as gastrointestinal bleeding, likely to be modulated by
the pharmacologic agents used around the time of PCI instead
of the chosen arterial access site.
The model identiﬁed 8 independent factors associated with
the development of vascular access site complications
including: elevated age, female gender, elevated troponin,
chronic kidney disease, whether a procedure was emergent,
prior PCI, diabetes, and peripheral artery disease. Several of
these factors, including elevated age, female gender, periph-
eral vascular disease, and whether a procedure was emergent
have been previously identiﬁed as being associated with
elevated procedural risk.8,22 Prior PCI has also previously
been shown to be associated with less risk of post-PCI
bleeding, similar to our ﬁndings.22
The risk algorithm presented here allows the calculation of
a speciﬁc risk of access site complications for a given patient
and makes explicit the contribution of each risk factor. We
believe that this model is highly actionable in clinical practice
because we intentionally chose to model only clinical
variables that would be available before the PCI, or even
routine coronary angiography, was performed. A prior risk
model predicting vascular access complications relies on
knowledge of the coronary anatomy as well as knowledge of
medication use that is often initiated during or around the
time of PCI.8 We have also intentionally excluded other factors
that are deﬁned at the time of the procedure, or are
procedural-related factors themselves. The femoral arterial
anatomy, the site of a femoral arteriotomy, and the decision
to use vascular closure devices are either deﬁned at the time
of angiography or during the PCI and thus are not useful for
preprocedural prediction.
The rate of transradial arterial access in this study
population was higher (17.8%) than the published rates
across the United States (<1.5%).17 When applying the model
that we developed for transfemoral arterial access site
complications to the entire population of PCI patients,
including those who received transradial access, we intended
to determine if clinicians in routine practice were employing a
strategy for the use of transradial arterial access that would
be expected to prevent the highest number of complications.
Instead, we found that the individuals at highest risk for
access site complications via a transfemoral approach were
the least likely to receive transradial access during PCI. This
pattern of use, known as the risk-treatment paradox, has been
described previously for other therapies including statin
treatment in the elderly,28 anticoagulation for atrial ﬁbrilla-
tion,29 and the use of bleeding avoidance strategies, such as
anticoagulation with bivalirudin, during PCI,30 and may
represent an important area for quality improvement.
Our observation led to us to explore several explanatory
hypotheses. First, we hypothesized that a desire to perform
the procedure quickly, particularly in patients presenting with
STEMI, led to increased rates of transfemoral access. In a
previous meta-analysis comparing clinical outcomes in
patients who undergo PCI with transradial compared with
A
B
C
Figure 3. Rate of femoral or radial access according to predicted
risk of transfemoral vascular access complications, stratiﬁed by
presentation with ST-segment myocardial infarction (STEMI). A,
Patients presenting with STEMI (n=2171). B, Patients presenting
without STEMI (n=14 386). C, Full study population excluding
patients receiving dialysis treatment (n=16 747).
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transfemoral arterial access, procedure times were longer in
the transradial group.14 The data presented in our analysis do
not support this hypothesis as the sole explanation of our
ﬁndings, however. We demonstrate that in those presenting
with both STEMI and those presenting for PCI without STEMI
(including both patients with stable coronary artery disease
and those with non-ST-segment elevation acute coronary
syndromes), patients at highest risk for access site compli-
cations via a transfemoral approach were most likely to
receive transfemoral access in each subgroup. We also
performed an analysis excluding patients receiving dialysis
treatment as these patients are often not candidates for
transradial arterial access due to the desire to preserve
possible hemodialysis access points for the future. After
excluding this population, patients at highest risk for access
site complications via a transfemoral approach were still most
likely to receive transfemoral access.
There are several other factors that may be driving our
ﬁndings. It is possible that the factors associated with access
site complications are themselves associated with increased
procedural complexity and treating physicians prefer to
perform complex cases (either due to patient presentation,
comorbidities, or anatomic factors) via a transfemoral
approach. We also hypothesize that these data reﬂect the
learning curve of physicians who are increasing the use of
transradial PCI over time, but who begin with simpler cases
while gaining experience. These data cannot adequately
address these hypotheses.
While an increase in the use of transradial approaches in
patients at high risk for femoral access complications would
likely reduce such complications, the choice of access site
should be weighed alongside other clinical considerations.
Weighing the technical success of the procedure, and
minimizing risk of nonaccess site adverse events such as
reinfarction or future stent thrombosis, may be more
important than small added risk of vascular access site
complications for certain patients. However, periprocedural
bleeding during PCI has been shown to be associated with
recurrent adverse cardiac events and elevated rates of all-
cause mortality.9,31–34 Furthermore, the chief beneﬁt of
radial access in randomized trials has been the prevention of
access site complications.13 Thus, since one of the primary
purposes of choosing radial arterial access compared with
femoral arterial access for PCI is to prevent vascular access
site complications, including bleeding, clinicians would
beneﬁt from the tools to make rational decisions in this
regard.
We acknowledge, however, that increasing the use of
transradial PCI is also not exactly akin to increasing the use
of evidence-based medication therapies, for instance. Tech-
nical expertise and proﬁciency are required before transradial
PCI can be safely performed, particularly in technically
challenging cases. Sites need to move from a stage early in
the transradial learning curve where operators perform the
simplest cases via a transradial approach to a “radial-ﬁrst”
stage where transradial access is the preferred method of
arterial access, as has been suggested by the recent
European Society of Cardiology Consensus Statement regard-
ing transradial PCI.35 From our analyses, it is difﬁcult to
determine where these 5 institutions are on the learning
curve for transradial PCI. Different research methodologies
will be needed to adequately address this question in the
future.
There are several other important limitations in these
analyses. Our study was observational in nature, and thus
direct comparisons of complication rates among transfemoral
and transradial PCI procedures may be subject to residual
confounding. Next, although our study describes a multicenter
experience including more than 17 000 patients undergoing
PCI in clinical practice, it was limited to 5 hospitals in
Massachusetts where transradial access utilization is higher
than the reported national average. In addition, while our model
was internally validated via bootstrapping, incorporates risk
factors that have been previously described as being associ-
ated with procedural complications, and compares favorably in
terms of discrimination and calibration of other PCI prediction
models,22,36,37 the study remains to be validated in an external
dataset. As such, our ﬁndings may not be generalizable to all
populations. Next, the clinical endpoints in this study were not
adjudicated independently, potentially leading to underreport-
ing particularly of less signiﬁcant access site complications.
Also, other factors that might inﬂuence vascular access site
complications were not considered in the models due to our
desire to use preprocedural factors only. Thus, some factors
that inﬂuence bleeding, such as anticoagulant and antiplatelet
agents as well as vascular closure devices, were not accounted
for in the models. Finally, longterm outcomes are unavailable
for this population so we do not know the inﬂuence of vascular
access site complications on a patient’s clinical status after
hospital discharge.
Conclusions
We developed and internally validated a model predicting risk
for the development of vascular access site complications
during PCI via a transfemoral approach. We then demon-
strated that among all patients who undergo PCI, those at
lowest risk for access site complications were most likely to
receive transradial arterial access while those at highest risk
for vascular access site complications were the most likely to
undergo transfemoral arterial access. If transradial arterial
access is to be employed rationally as a strategy to avoid
vascular access site complications, there is signiﬁcant room
for improvement in its use.
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